⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344838 | 0.79 | — | — | |
| SCHEMBL2286902 | 0.79 | — | — | |
| SCHEMBL1810655 | 0.77 | — | — | |
| SCHEMBL18585315 | 0.75 | — | — | |
| SCHEMBL29180900 | 0.75 | — | — | |
| SCHEMBL2347883 | 0.75 | — | — | |
| SCHEMBL28481053 | 0.73 | RAPGEF4 (0.33) | — | |
| SCHEMBL297382 | 0.72 | — | — | |
| SCHEMBL28040427 | 0.70 | RAPGEF4 (0.32) | — | |
| SCHEMBL9784274 | 0.69 | ACHE (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2009538308-A | — | — | 2009-11-05 | — | — | JP | claimed |
| US-20090233906-A1 | IMIDAZOAZEPINONE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-09-17 | — | — | US | claimed |
| EP-2021343-A1 | IMIDAZOAZEPHINONE COMPOUNDS | Eisai Research Institute Of Boston, Inc. (US) | 2009-02-11 | — | — | EP | claimed |
| WO-2007139813-A1 | IMIDAZOAZEPHINONE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD (JP) | 2007-12-06 | — | — | WO | claimed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4278014-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-4277901-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| WO-2022152821-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022152822-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| US-20090131405-A1 | IMIDAZOAZEPINONE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-2021003-A2 | IMIDAZOAZEPHINONE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2009-02-11 | — | — | EP | disclosed |
| EP-2021343-A1 | IMIDAZOAZEPHINONE COMPOUNDS | Eisai Research Institute Of Boston, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007139813-A1 | IMIDAZOAZEPHINONE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD (JP) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139948-A2 | IMIDAZOAZEPINONE COMPOUNDS | EISAI R & D MANAGEMENT CO., LTD (JP) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139833-A2 | IMIDAZOAZEPHINONE COMPOUNDS | EISAI R & D MANAGEMENT CO., LTD (JP) | 2007-12-06 | — | — | WO | disclosed |
| EP-1023267-A1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL S.A. (CH) | 2000-08-02 | — | — | EP | disclosed |
| WO-1999019302-A1 | PYRIDYL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CERMOL S.A. (CH) | 1999-04-22 | — | — | WO | disclosed |